Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Recruiting 5Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 18Gastrointestinal 1

Conditions

Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 86Bevacizumab 66Capecitabine 65Fluorouracil 48tislelizumab 41Gemcitabine 40Drug Therapy 39Leucovorin 38sintilimab 35Irinotecan 34lenvatinib 27Cisplatin 27HMPL-013 25S 1 (combination) 23camrelizumab 22Immune Checkpoint Inhibitors 21irinotecan sucrosofate 20apatinib 20Surgical Procedures, Operative 20Radiotherapy 20Injections 20130-nm albumin-bound paclitaxel 20toripalimab 19Paclitaxel 18Folfox protocol 17pembrolizumab 15Immunotherapy 15Cetuximab 15Specimen Handling 14regorafenib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × pertuzumab × Gastrointestinal × Clear all
NCT07129018 2025-08-19

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
63 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡